From Warning Letter to Boardroom: What Environmental Monitoring, Trending, and Sampling Problems Really Cost — And How to Fix Them

Authers: To be included

A combined review of what U.S. FDA warning letters found, what they cost the companies involved in money and reputation, and a practical, step-by-step plan to fix the root causes.

Disclaimer

This review article is AI assisted for: researching publicly available data, reports, press releases, regulatory and stock-exchange disclosures, market reaction, analyst commentary, reputational notes, and sales/revenue reports; structuring the report; refining ideas; and formatting the content into clear, professional, presentable language. All facts are drawn from publicly available sources, each credited individually in the References section at the end of this report. This report does not replace independent verification, legal advice, or financial advice, and readers are encouraged to consult the original sources linked throughout.

Table of Contents

Executive Summary

Every year, the U.S. Food and Drug Administration (FDA) issues warning letters to drug companies whose factories do not meet basic safety and quality rules. These rules are often called, Current Good Manufacturing Practice (CGMP) This report looks closely at one specific type of problem found in these letters: failures in checking for microorganisms in the air and on surfaces (called environmental monitoring), failures in collecting test samples the right way (sampling), and failures in evaluating patterns in test results over time (trending).

This review is built in three parts, in a simple order: first, what happened; second, what it cost; and third, what companies can do about it.

- Part 1 explains, what these warning letters found using real company names and their official FDA case numbers, called MARCS-CMS numbers, so every claim can be checked.
- Part 2 shows what these letters cost the companies involved, how much their stock price dropped, whether they had to recall products, and how the media reports affected their reputation.
- Part 3 offers a practical, step-by-step plan built using a proven problem-solving method called Human Centric Design Thinking for how any company can resolve these problems before they turn into a warning letter.

The single biggest lesson from this review: problems with checking for microorganisms and tracking test results over time are rarely the whole story. They are usually the early warning sign of a bigger issue and companies that treat them as a box-ticking exercise, rather than a real safety check, are the ones that end up with a warning letter, a stock price drop, or a product recall.

Part 1: What Happened — The Warning Letters

An FDA warning letter is an official notice sent to a company when FDA inspectors find serious problems at a factory. It is one step below the most serious action FDA can take (stopping a company from selling in the US). This review looked at 60 warning letters sent to drug companies between 2021 and 2026, and focused closely on the ones that mentioned three specific problems:

- Environmental monitoring — regularly checking the air and surfaces in a drug-manufacturing area for (especially in a sterile, or “aseptic,” area) microorganisms.
- Sampling — collecting test samples from the right place, at the right time, in the right way.
- Trending — looking at test results over weeks and months to observe a pattern before it becomes a bigger problem.

What the Numbers Show

Out of the 60 letters reviewed, chart below is how often each type of problem came up:



Fig 1: Observation Themes Across Reviewed Warning Letters

Checking for microorganisms in the air (“environmental monitoring”) and collecting samples correctly came up less often on their own but as the examples below show, they are very often the hidden cause behind the much more common problem of microorganisms actually being found in finished products.

Real Examples

1. Somerset Therapeutics Private Limited (MARCS-CMS 711340, September 04, 2025)[1]: FDA found that the company's air-testing equipment failed 16 times during one inspection, and nobody investigated why. The results were simply filed as “for information only.”

2. Wizcure Pharmaa Private Limited (MARCS-CMS 726378, June 24, 2026)[2]: FDA found that test data had been changed to hide the actual results, and that the company was not regularly checking for microorganisms at all. This later led to a recall of eye drops sold under the brand names Vista Tear and BioGlow.

3. Eugia Pharma Specialities Limited (MARCS-CMS 681905, August 15, 2024)[3], a factory owned by Aurobindo Pharma: workers wrote down air-quality test results from the wrong time and the wrong place, then changed the timestamps to hide it. FDA had already classified this factory as “Official Action Indicated” (OAI) its most serious inspection rating short of blocking imports outright before this warning letter was sent.

4. Intas Pharmaceuticals Limited (MARCS-CMS 652067, July 28, 2023)[4]: An employee was seen pouring a chemical into a trash bin to destroy paper records before inspectors could see them. The destroyed records included Environmental Monitoring System (EMS) documents, and separately, FDA found the lab’s colony-forming-unit (CFU) counts in its environmental monitoring data did not match what inspectors observed on re-count.

5. Kilitch Healthcare India Limited (MARCS-CMS 672956, March 28, 2024)[5]: FDA found unsafe conditions and signs that lab records had been changed after the fact. This led to a nationwide recall of more than 27 eye drop products sold at major US pharmacy chains. The unsafe conditions specifically included residue found next to HEPA filters in an ISO 5 (highest cleanliness) manufacturing area, and staff working ungowned in areas meant to be tightly controlled for contamination.

6. Cipla Limited (MARCS-CMS 660904, November 17, 2023)[6]: Test results from routine safety checks were collected but never carefully reviewed before products were shipped. FDA separately found Cipla failed to prevent microbiological contamination in products

meant to be sterile, citing a pattern of media-fill contamination incidents and environmental monitoring (EM) data that was never substantively evaluated.

7. Centrient Pharmaceuticals India Private Limited (MARCS-CMS 640196, December 07, 2022)[7]: The company's method for detecting leftover antibiotic residue on equipment was never proven to actually work meaning it could have missed contamination. This kind of residue testing also matters for excipients the inactive ingredients, like fillers or preservatives, mixed into a medicine. Poor document control also extended to records kept near the facility's microbiology laboratory, adding to concerns about the reliability of its contamination-testing data.

Warning Letters reviewed

The seven examples above give the flavour of what these letters found. The table below lists all 48 warning letters (from 45 companies) from this review that touch on environmental monitoring (EM), microbiology, sampling, or trending out of the 60 total letters studied. Company names are shown with their official FDA MARCS-CMS number, matching how they appear throughout this report.

Company (MARCS-CMS Number)	MARCS-CMS #	Letter Date	Related To	Reference #
Aurobindo Pharmaceutical Limited (MARCS-CMS 618091, January 12, 2022)	618091	January 12, 2022	Micro, Trending	30
Indiana Chem-Port (MARCS-CMS 618173, February 02, 2022)	618173	February 02, 2022	Micro, Sampling, Trending	31
Centrient Pharmaceuticals India Private Limited (MARCS-CMS 640196, December 07, 2022)	640196	December 07, 2022	EM, Micro, Trending	32
Champaklal Maganlal Homeo Pharmacy Private Limited (MARCS-CMS 652319), April 10, 2023	652319	April 10, 2023	Micro	33
Centaur Pharmaceuticals Private Ltd. (MARCS-CMS 651080, June 05, 2023)	651080	June 05, 2023	Micro, Trending	34
Medgel Private Limited (MARCS-CMS 654085, July 20, 2023)	654085	July 20, 2023	Micro, Trending	35
Baxter Healthcare Corporation (MARCS-CMS 654136, July 25, 2023)	654136	July 25, 2023	Micro, Trending	36
Centaur Pharmaceuticals Private Ltd. (MARCS-CMS 655231, July 25, 2023)	655231	July 25, 2023	Micro, Trending	37
Intas Pharmaceuticals Limited (MARCS-CMS 652067, July 28, 2023)	652067	July 28, 2023	EM, Micro, Sampling, Trending	38

Orchid Lifesciences (MARCS-CMS 663478, August 03, 2023)	663478	August 03, 2023	Micro	39
Suhan Aerosol (MARCS-CMS 663489, August 03, 2023)	663489	August 03, 2023	Micro	40
Sun Pharmaceutical Industries Ltd. (MARCS-CMS 636199, October 16, 2023)	636199	October 16, 2023	EM, Micro, Trending	41
Cipla Limited (MARCS-CMS 660904, November 17, 2023)	660904	November 17, 2023	EM, Micro, Sampling, Trending	42
Intas Pharmaceuticals Limited (MARCS-CMS 662868, November 21, 2023)	662868	November 21, 2023	Micro, Sampling, Trending	43
Patcos Cosmetics Pvt. Ltd. (MARCS-CMS 669465, December 15, 2023)	669465	December 15, 2023	Micro	44
Madhu Instruments Private Limited (MARCS-CMS 659694, February 01, 2024)	659694	February 01, 2024	Micro	45
Kilitch Healthcare India Limited (MARCS-CMS 672956, March 28, 2024)	672956	March 28, 2024	EM, Micro, Sampling, Trending	46
Natco Pharma Limited (MARCS-CMS 672564, April 08, 2024)	672564	April 08, 2024	Micro, Trending	47
Velocity Pharma LLC (MARCS-CMS 676434, July 17, 2024)	676434	July 17, 2024	Micro	48
Eugia Pharma Specialities Limited (MARCS-CMS 681905, August 15, 2024)	681905	August 15, 2024	EM, Micro, Trending	49
Unexo Lifesciences, Private Limited (MARCS-CMS 688163, November 06, 2024)	688163	November 06, 2024	Micro, Trending	50
Micro Orgo Chem (MARCS-CMS 686458, December 03, 2024)	686458	December 03, 2024	Micro, Trending	51
Indoco Remedies Limited (MARCS-CMS 691594, December 16, 2024)	691594	December 16, 2024	Micro, Trending	52
Akron Formulations India Private Limited (MARCS-CMS 693938, December 17, 2024)	693938	December 17, 2024	Micro, Sampling, Trending	53
Bhargava Phytolab Private Limited (MARCS-CMS 691610, December 18, 2024)	691610	December 18, 2024	Micro	54
Viatris, Inc. (MARCS-CMS 690897, December 19, 2024)	690897	December 19, 2024	Micro, Trending	55
Global Calcium Pvt. Limited (MARCS-CMS 692000, January 16, 2025)	692000	January 16, 2025	Micro, Trending	56
Granules India Limited (MARCS-CMS 697115), February 26, 2025	697115	February 26, 2025	Micro, Trending	57
Aspen Biopharma Labs Private Limited (MARCS-CMS 698665, March 05, 2025)	698665	March 05, 2025	Micro, Trending	58

Macsen Drugs (MARCS-CMS 698202, March 05, 2025)	698202	March 05, 2025	Trending	59
Mentha & Allied Products Private Ltd. (MARCS-CMS 700242, April 16, 2025)	700242	April 16, 2025	Micro, Sampling, Trending	60
Kenil Healthcare Private Limited (MARCS-CMS 704786, June 12, 2025)	704786	June 12, 2025	Micro, Trending	61
Glenmark Pharmaceuticals Limited (MARCS-CMS 708270, July 11, 2025)	708270	July 11, 2025	Micro, Sampling, Trending	62
Shiva Analyticals Private Limited (MARCS-CMS 707857, July 23, 2025)	707857	July 23, 2025	Trending	63
Hikal Limited (MARCS-CMS 709370, August 20, 2025)	709370	August 20, 2025	Micro, Trending	64
Amneal Pharmaceuticals, LLC (MARCS-CMS 709894, August 27, 2025)	709894	August 27, 2025	Micro, Sampling, Trending	65
Somerset Therapeutics Private Limited (MARCS-CMS 711340, September 04, 2025)	711340	September 04, 2025	EM, Micro, Trending	66
Cdymax India Pharma Private Limited (MARCS-CMS 715022, November 13, 2025)	715022	November 13, 2025	Micro, Sampling, Trending	67
Tentamus India Private Limited (MARCS-CMS 720463, March 03, 2026)	720463	March 03, 2026	Micro, Trending	68
Flowchem Pharma Private Limited (MARCS-CMS 720719, March 11, 2026)	720719	March 11, 2026	Micro, Trending	69
Patcos Cosmetics Pvt. Ltd. (MARCS-CMS 718220, March 12, 2026)	718220	March 12, 2026	Micro, Sampling, Trending	70
Alchymars ICM SM Private Limited (MARCS-CMS 724429, May 21, 2026)	724429	May 21, 2026	Micro, Trending	71
Gopaldas Visram & Co., Ltd. (MARCS-CMS 721755, June 02, 2026)	721755	June 02, 2026	Micro, Trending	72
Umendra Life Sciences Private Limited (MARCS-CMS 721752, June 02, 2026)	721752	June 02, 2026	Micro	73
Zydus Lifesciences Limited (MARCS-CMS 722576, June 02, 2026)	722576	June 02, 2026	Micro, Trending	74
Wizcure Pharmaa Private Limited (MARCS-CMS 726378, June 24, 2026)	726378	June 24, 2026	EM, Micro, Trending	75
BioMylz Pvt. Ltd. (MARCS-CMS 729483, July 13, 2026)	729483	July 13, 2026	Micro, Sampling, Trending	76
Shimoga Chemicals (MARCS-CMS 727904, July 13, 2026)	727904	July 13, 2026	Micro, Sampling, Trending	77

Table 1: List of Warning letters related to Micro, EM Sampling and Trending

Part 2: What It Cost — Money and Reputation

A warning letter is not just a paperwork problem. For companies, whose shares are publicly traded, news of a warning letter often causes an immediate reaction in the stock market. For companies that are privately owned, the cost shows up differently through product recalls, lawsuits, and damage to their reputation in the press. The companies discussed in this part are the same ones covered in Part 1 all tied to environmental monitoring, microbiology, sampling, or trending failures so the two parts of this report can be read side by side.

This part of the report looks at 38 companies in total: 13 companies whose shares trade on a public stock market, and 25 privately owned companies. For the public companies, we tracked the actual stock price movement. For the private companies, we searched for real news coverage, recalls, and other public consequences.

How Much Did Share Prices Drop?

The table below shows how much each company's stock price moved on the day (or in the days after) its warning letter became public news.

Company (MARCS-CMS Number)	Share Price Move	Reference #
Sun Pharmaceutical Industries Ltd. (MARCS-CMS 636199)	-1.95%	8
Cipla Limited (MARCS-CMS 660904)	-0.21% same day; -8% over the following week	9
Aurobindo Pharmaceutical Limited (MARCS-CMS 618091)	-5%	10
Eugia Pharma Specialities Limited (MARCS-CMS 681905, Aurobindo unit)	-6.4% at the lowest point that day	11
Glenmark Pharmaceuticals Limited (MARCS-CMS 708270)	-0.56% (very little reaction)	12
Zydus Lifesciences Limited (MARCS-CMS 722576)	-2.24% at the lowest point that day	13
Natco Pharma Limited (MARCS-CMS 672564)	-1.6%	14
Granules India Limited (MARCS-CMS 697115)	-7.5% (the largest same-day drop in this review)	15
Indoco Remedies Limited (MARCS-CMS 691594)	-8.4% at the lowest point that day	16

Company (MARCS-CMS Number)	Share Price Move	Reference #
Viatris, Inc. (MARCS-CMS 690897)	-15% when the true financial cost was revealed two months later	17
Hikal Limited (MARCS-CMS 709370)	-1.4%	20

Table 2: Company wise Share Price Drop Following Warning Letter Disclosure



Fig 2: Share Price Drop Following Warning Letter Disclosure

The Biggest Story: Viatris

Viatris, Inc. (MARCS-CMS 690897, December 19, 2024)[17] is the most serious case in this entire review. In December 2024, FDA sent a warning letter about the company's factory in Indore, India, and also stopped 11 products including a major cancer medicine from entering the US. At the time, Viatris told investors this would not affect its yearly financial targets.

Two months later, in February 2025, the real picture came out: the company had lost roughly $470 million in sales and $325 million in profit because of this one factory. The stock price fell about 15% in a single day when investors learned the true cost. Shareholders have since filed a

lawsuit against the company, arguing they were misled about how serious the problem really was.

When the Company Isn't Publicly Traded: What Happens Instead

Intas Pharmaceuticals Limited (MARCS-CMS 652067[21]) is privately owned, so it has no stock price to track. But the consequences were still severe: the company's factory problems contributed to a nationwide shortage of chemotherapy medicines in the United States, serious enough that a US Senator wrote directly to the FDA Commissioner asking what was being done about it.[29]

Kilitch Healthcare India Limited (MARCS-CMS 672956, March 28, 2024)[22] is also privately owned. Its problems led to a rare direct warning from FDA to American consumers, telling them by name not to buy certain eye drop brands, and to a recall covered by major US health-news outlets.

Aspen Biopharma Labs Private Limited (MARCS-CMS 698665, March 05, 2025)[23] admitted in writing to FDA that it had backdated a quality document. The company then recalled all its US products and de-registered its factory with FDA entirely effectively leaving the US market.

Global Calcium Pvt. Limited (MARCS-CMS 692000, January 16, 2025)[24] admitted that a manager had ordered staff to falsify production records to earn a financial bonus. The story was covered by STAT News, a well-respected health-news outlet.

Part 3: How to Fix It — A Step-by-Step Plan

The problems described in Parts 1 and 2 keep happening across different companies. That means the fix should not just be about punishing one company after the fact it should be about redesigning how the work actually gets done, based on how the people (Human Centric) doing the work really experience it.

To do this, we used a well-known problem-solving method called Human Centric Design Thinking. It has four simple steps: understand the people involved, clearly define the real problem, come up with solutions, and test those solutions on a small scale before rolling them out everywhere.

Step 1: Understand the People Involved

We envisaged to create an empathy map for a typical, hardworking lab technician who checks for microorganisms every day, and thought about what they might say, think, do, and feel using a structured Question Ladder and Shadowing Observation Plan.

EMPATHY MAP — Front-Line EM/QC Analyst (Composite Persona)

SAYS	THINKS
"We follow the SOP as written."	"Why are we sampling the same spot every time?"
"The schedule says sample here."	"Nobody reviews these trends until audit season."
"If a sampler fails, we just redo it."	"I don't have time to investigate an aborted sample."
"The checklist doesn't ask why, just where and when."	"This isn't really about compliance, it's about who gets blamed if something goes wrong."
"I've never been told what happens to the data after I log it."	"I wonder if anyone actually looks at last year's data before this year's audit."
"We redo a failed sampler and move on — nobody said to report it."	"If I flag too many issues, will it look like I'm bad at my job?"

DOES	FEELS
Runs monitoring rounds against a fixed checklist	Rushed — EM is one of many competing duties
Logs pass/fail results into paper or legacy systems	Unsure whether raising a concern will be welcomed
Escalates only when a limit is breached, not when a pattern looks odd	Disconnected from what happens to the data after logging it
Repeats the exact same sampling locations shift after shift without questioning them	Anxious about being the one blamed if a trend is discovered late
Signs off on paperwork at the end of a rushed round without double-checking entries	Proud when a round goes smoothly and the data comes out clean
Relies on memory to fill in details after the round instead of recording in real time	Isolated — feels like the sole owner of a process nobody else really understands

Fig 3: EMPATHY MAP — Front-Line EM/QC Analyst (Composite Persona)

Step 2: Creating Affinity Map

Out of the 60 letters reviewed, the observations are categorized in 12 Themes as presented in Fig 1.

Each of those 12 themes was assigned to one of 4 broader "systemic gap" clusters, based on what kind of failure it represents and presented in Fig 4: AFFINITY DIAGRAM.

Detection Gaps (can the company even see the problem?) — Environmental Monitoring, Sampling Procedures, Component/Raw Material Testing

Analysis Gaps (do they understand what they see?) — Data Integrity/Trending of Failures, Laboratory Controls & Method Verification

Integrity Gaps (can the record be trusted?) — Documentation & Batch Records, Microbiological Failure

Governance Gaps (does the system respond?) — Quality Unit Oversight, CAPA/Response Adequacy, Process/Cleaning Validation, Labeling/Unapproved Drug/Misbranding, Clinical

investigator/Informed Consent.

AFFINITY DIAGRAM — 12 Observation Themes Clustered Into 4 Systemic Gaps

DETECTION GAPS (can we see the problem?)	ANALYSIS GAPS (do we understand it?)
Environmental Monitoring (8 letters) — e.g., Somerset Therapeutics: 16 aborted air-sampler events left uninvestigated	Data Integrity / Trending of Failures (40 letters) — e.g., Intas Pharmaceuticals: torn/discarded CGMP records tied to the EM system
Sampling Procedures (13 letters) — e.g., Kilitch Healthcare: no documented rationale for EM sampling locations	Laboratory Controls & Method Verification (28 letters) — e.g., BioMylz: no testing for objectionable microorganisms
Component / Raw Material Testing (20 letters) — e.g., Centrient Pharmaceuticals: unvalidated beta-lactam residue detection method	Trend review treated as a quarterly/annual filing exercise rather than continuous analysis
Missing method-validation for target contaminants before sampling begins	Zero-excursion records treated as reassurance rather than a prompt for scrutiny
No differentiation between routine and worst-case, risk-based sampling points	No cross-comparison of EM results against historical facility baseline before release
Backup equipment (air samplers) not qualified to the same standard as primary units	Statistical/trend dashboards largely absent from routine, day-to-day review

INTEGRITY GAPS (can we trust the record?)	GOVERNANCE GAPS (does the system respond?)
Documentation & Batch Records (38 letters) — e.g., Aspen Biopharma Labs: admitted backdating of a QC lab document	Quality Unit Oversight / Weaknesses (46 letters)
Microbiological Failure (46 letters) — e.g., Wizcure Pharmaa: falsified aseptic test data	CAPA / Response Adequacy (51 letters) — e.g., Kenil Healthcare: recall committed to, but follow-through never confirmed
Paper-to-electronic transcription creates unverified, unaudited gaps	Process / Cleaning Validation (40 letters)
Second-person review often amounts to a signature only, not a substantive re-check	Labeling / Unapproved Drug / Misbranding (40 letters) — e.g., Silkrute, Indiangoods.shop desk-review letters
Deleted or altered electronic files (e.g., Global Calcium) undermine the audit trail	Clinical Investigator / Informed Consent (4 letters) — a different domain, but the same root governance failure
Inconsistent labeling and control-numbering across shared documents	Repeat-offender pattern: the same facility cited years apart for the same category of failure (e.g., Alchymars, Patcos)
	Quality unit lacks the authority to halt release despite documented, open deviations

Fig 4: AFFINITY DIAGRAM — 12 Observation Themes Clustered Into 4 Systemic Gaps

Step 3: Define the Real Problem

The real, underlying problem is that companies are not consistently checking the right places, at the right time, and are not looking closely enough at test results over time to catch problems early. The main root causes we found, are presented below as a problem Tree.



Fig 5: PROBLEM TREE — Environmental Monitoring & Sampling Failures

Step 4: Come Up With Solutions

A SCAMPER table is developed for various possible ideas consisting of 42 solutions which are condensed to 7 ideas, one per SCAMPER technique, each tied to a specific real finding from the letters reviewed.

Below are the most practical ideas that came out of this review, grouped by type of change:

Idea Type	Practical Suggestion
Replace (Substitute)	Stop testing the same spot every time out of habit; test the highest-risk spots instead and change them based on real risk.
Combine	Make trend review a required, signed-off step of every batch release not a separate task nobody remembers to do.
Adapt (Copy from elsewhere)	Borrow the 'near miss' reporting habit used in hospitals: when a test fails to run properly, treat it as a reportable event, not routine.
Improve (Modify / Magnify/Minify)	Give every team member visibility into trend data on a shared screen, not just during a yearly audit.
Reuse (Put to Another Use)	Use the same secure record-keeping system already used elsewhere in the company, so results can't be edited after the fact.
Remove (Eliminate)	Get rid of paper records for the highest-risk areas; require typing results in directly at the time of testing.
Flip it around (Reverse)	Treat an unusually perfect record zero problems for years as a reason to look closer, not a reason to relax.

Table 3: List of most practical ideas condensed from 42 ideas SCAMPER

Step 4: Test It Before Rolling It Out Everywhere

Before making these changes company-wide, we recommend testing them at one factory first, and gathering honest feedback as presented below.

FEEDBACK CAPTURE GRID — Piloting the Redesigned EM/Sampling Program	
LIKES	**CRITICISMS**
Sampling rationale now documented and visible to the team	More documentation time per round, initially
Trend dashboard makes drift easy to spot early	Some staff unclear who owns trend review
Mobile checklist reduces double-entry between paper and LIMS	Dashboard requires IT support not readily available on all shifts
Aborted events are now investigated same-day instead of silently redone	Risk-based site selection felt arbitrary without more explanation
New joint QA/production review builds shared ownership of trend data	Weekly review cadence feels like 'more meetings' to some staff
Training now explains the 'why', not just the mechanical steps	Legacy paper records still exist in parallel, creating confusion
QUESTIONS	**IDEAS**
Who signs off when a trend flag is raised?	Add a mobile checklist with photo capture at each site
How will this integrate with the existing LIMS?	Tie aborted-sample events directly into the CAPA queue
What happens to historical paper records once digitized?	Build a one-tap 'aborted event' button into the mobile app for immediate logging
Will backup equipment be qualified to the same standard as primary?	Add automated alerts when a trend approaches, not just breaches, a limit
How often will the risk-based sampling plan itself be re-reviewed?	Create a shared onboarding video walking new hires through the 'why' of each step
Who owns the escalation if a location is flagged repeatedly?	Pilot a peer-review buddy system for plate reading before full rollout

Fig 6: FEEDBACK CAPTURE GRID — Piloting the Redesigned EM/Sampling Program

Frequently Asked Questions

1. What exactly is an FDA warning letter?

It is an official notice from the U.S. Food and Drug Administration telling a company that inspectors found serious problems at a factory that need to be fixed. It is a formal warning, one step before FDA takes stronger action, such as blocking products from entering the US.

2. Why does checking for microorganisms (environmental monitoring) matter so much?

Because it is often the earliest possible sign that something has gone wrong before it reaches the finished product. Skipping or rushing this step means problems are caught later sometimes only after the product has already reached a patient.

3. Does a warning letter always hurt a company's stock price?

Not always. In this review, the drop ranged from almost nothing (Glenmark, -0.56%) to very serious (Viatris, -15% once the full cost became known). The size of the reaction usually depends on how serious the problem is and whether the company was honest about it right away.

4. What happens to a company that isn't publicly traded?

It won't see a stock price move, but the consequences can still be serious product recalls, lawsuits from customers, and damage to its reputation in the news, as seen with Intas Pharmaceuticals, Kilitch Healthcare, and Aspen Biopharma Labs in this report.

5. What is the single most useful fix companies can make right now?

Treat any failed or skipped test as something that must be investigated immediately not something to simply redo and move on from. Several of the most serious cases in this report trace back to exactly this habit.

References

Full credit is given below to every original source used in this report. Click any reference number in the text to jump here or click the source link below to visit the original article.

1. U.S. FDA — U.S. Food and Drug Administration — Warning Letter to Somerset Therapeutics Private Limited (MARCS-CMS 711340), September 4, 2025.

2. U.S. FDA — U.S. Food and Drug Administration — Warning Letter to Wizcure Pharmaa Private Limited (MARCS-CMS 726378), June 24, 2026.

3. U.S. FDA — U.S. Food and Drug Administration — Warning Letter to Eugia Pharma Specialities Limited (MARCS-CMS 681905), August 15, 2024.

4. U.S. FDA — U.S. Food and Drug Administration — Warning Letter to Intas Pharmaceuticals Limited (MARCS-CMS 652067), July 28, 2023.

5. U.S. FDA — U.S. Food and Drug Administration — Warning Letter to Kilitch Healthcare India Limited (MARCS-CMS 672956), March 28, 2024.

6. U.S. FDA — U.S. Food and Drug Administration — Warning Letter to Cipla Limited (MARCS-CMS 660904), November 17, 2023.

7. U.S. FDA — U.S. Food and Drug Administration — Warning Letter to Centrient Pharmaceuticals India Private Limited (MARCS-CMS 640196), December 7, 2022.

8. Business Today — Business Today — “Sun Pharma shares slip 2% after USFDA issues warning letter for Halol facility,” December 19, 2022.

9. Outlook Business — Outlook Business — “Cipla's shares tumble as Indore unit gets warning letter from USFDA.”

10. Business Standard — Business Standard — “Aurobindo Pharma down 5% on USFDA warning letter for Hyderabad unit,” January 14, 2022.

11. Business Standard — Business Standard — “Aurobindo Pharma stock tanks 6% after unit gets warning letter from USFDA,” August 16, 2024.

12. Business Standard — Business Standard — “Glenmark Pharma receives warning letter from USFDA for Indore facility,” July 14, 2025.

13. Business Standard — Business Standard — “Zydus Lifesciences slips after Baddi unit receives warning letter from US FDA,” June 3, 2026.

14. Upstox — Upstox — “Natco Pharma drops 2% after USFDA issues warning letter for Kothur facility.”

15. Business Standard — Business Standard — “Granules down 7% after USFDA issues warning letter for Gagillapur facility,” February 28, 2025.

16. Business Standard — Business Standard — “Indoco Remedies plunges 8% after warning letter from USFDA for Goa unit,” December 17, 2024.

17. ZLK (Levi & Korsinsky) — Levi & Korsinsky — Viatris, Inc. (VTRS) Securities Class Action Lawsuit Update, Case No. 2:25-cv-00466.

18. RAPS — Regulatory Affairs Professionals Society (RAPS) — “FDA warns Intas, Centaur, and Baxter over GMP violations,” August 2023.

19. FiercePharma — FiercePharma — “Amneal gets warning letter related to recalls of its antibacterial products.”

20. Business Upturn — Business Upturn — “Hikal shares fall over 2% after US FDA issues warning letter for Jigani facility.”

21. BioSpace — BioSpace — “Intas Pharmaceuticals hit with another FDA warning letter, put on import alert.”

22. AARP — AARP — “FDA recalls dozens of eye drops,” October 2023.

23. FiercePharma — FiercePharma — “India's Aspen Biopharma Labs hit with warning letter citing infrastructure, contamination.”

24. STAT News — STAT News (Pharmalot) — “FDA cites Global Calcium, an Indian pharmaceutical ingredients maker,” February 10, 2025.

25. MedShadow — MedShadow Foundation — FDA Recalls and Warnings roundup (includes Wizcure Pharmaa).

26. RAPS — Regulatory Affairs Professionals Society (RAPS) — “FDA warns Centrient over GMP issues at Indian facility,” December 2022.

27. FiercePharma — FiercePharma — “FDA puts India's Wintac (now Somerset Therapeutics) on blast for lackadaisical probe into bacterial contamination.”

28. Pharmaceutical Online — Pharmaceutical Online — “Trends in FDA FY2025 Warning Letters” (includes Kenil Healthcare).

29. U.S. Senate — Office of Senator Raphael Warnock — Letter to FDA Commissioner Robert Califf regarding the chemotherapy drug shortage, August 24, 2023.

30. U.S. Food and Drug Administration — Warning Letter to Aurobindo Pharmaceutical Limited (MARCS-CMS 618091), January 12, 2022.

31. U.S. Food and Drug Administration — Warning Letter to Indiana Chem-Port (MARCS-CMS 618173), February 02, 2022.

32. U.S. Food and Drug Administration — Warning Letter to Centrient Pharmaceuticals India Private Limited (MARCS-CMS 640196), December 07, 2022.

33. U.S. Food and Drug Administration — Warning Letter to Champaklal Maganlal Homeo Pharmacy Private Limited (MARCS-CMS 652319), April 10, 2023.

34. U.S. Food and Drug Administration — Warning Letter to Centaur Pharmaceuticals Private Ltd. (MARCS-CMS 651080), June 05, 2023.

35. U.S. Food and Drug Administration — Warning Letter to Medgel Private Limited (MARCS-CMS 654085), July 20, 2023.

36. U.S. Food and Drug Administration — Warning Letter to Baxter Healthcare Corporation (MARCS-CMS 654136), July 25, 2023.

37. U.S. Food and Drug Administration — Warning Letter to Centaur Pharmaceuticals Private Ltd. (MARCS-CMS 655231), July 25, 2023.

38. U.S. Food and Drug Administration — Warning Letter to Intas Pharmaceuticals Limited (MARCS-CMS 652067), July 28, 2023.

39. U.S. Food and Drug Administration — Warning Letter to Orchid Lifesciences (MARCS-CMS 663478), August 03, 2023.

40. U.S. Food and Drug Administration — Warning Letter to Suhan Aerosol (MARCS-CMS 663489), August 03, 2023.

41. U.S. Food and Drug Administration — Warning Letter to Sun Pharmaceutical Industries Ltd. (MARCS-CMS 636199), October 16, 2023.

42. U.S. Food and Drug Administration — Warning Letter to Cipla Limited (MARCS-CMS 660904), November 17, 2023.

43. U.S. Food and Drug Administration — Warning Letter to Intas Pharmaceuticals Limited (MARCS-CMS 662868), November 21, 2023.

44. U.S. Food and Drug Administration — Warning Letter to Patcos Cosmetics Pvt. Ltd. (MARCS-CMS 669465), December 15, 2023.

45. U.S. Food and Drug Administration — Warning Letter to Madhu Instruments Private Limited (MARCS-CMS 659694), February 01, 2024.

46. U.S. Food and Drug Administration — Warning Letter to Kilitch Healthcare India Limited (MARCS-CMS 672956), March 28, 2024.

47. U.S. Food and Drug Administration — Warning Letter to Natco Pharma Limited (MARCS-CMS 672564), April 08, 2024.

48. U.S. Food and Drug Administration — Warning Letter to Velocity Pharma LLC (MARCS-CMS 676434), July 17, 2024.

49. U.S. Food and Drug Administration — Warning Letter to Eugia Pharma Specialities Limited (MARCS-CMS 681905), August 15, 2024.

50. U.S. Food and Drug Administration — Warning Letter to Unexo Lifesciences, Private Limited (MARCS-CMS 688163), November 06, 2024.

51. U.S. Food and Drug Administration — Warning Letter to Micro Orgo Chem (MARCS-CMS 686458), December 03, 2024.

52. U.S. Food and Drug Administration — Warning Letter to Indoco Remedies Limited (MARCS-CMS 691594), December 16, 2024.

53. U.S. Food and Drug Administration — Warning Letter to Akron Formulations India Private Limited (MARCS-CMS 693938), December 17, 2024.

54. U.S. Food and Drug Administration — Warning Letter to Bhargava Phytolab Private Limited (MARCS-CMS 691610), December 18, 2024.

55. U.S. Food and Drug Administration — Warning Letter to Viatris, Inc. (MARCS-CMS 690897), December 19, 2024.

56. U.S. Food and Drug Administration — Warning Letter to Global Calcium Pvt. Limited (MARCS-CMS 692000), January 16, 2025.

57. U.S. Food and Drug Administration — Warning Letter to Granules India Limited (MARCS-CMS 697115), February 26, 2025.

58. U.S. Food and Drug Administration — Warning Letter to Aspen Biopharma Labs Private Limited (MARCS-CMS 698665), March 05, 2025.

59. U.S. Food and Drug Administration — Warning Letter to Macsen Drugs (MARCS-CMS 698202), March 05, 2025.

60. U.S. Food and Drug Administration — Warning Letter to Mentha & Allied Products Private Ltd. (MARCS-CMS 700242), April 16, 2025.

61. U.S. Food and Drug Administration — Warning Letter to Kenil Healthcare Private Limited (MARCS-CMS 704786), June 12, 2025.

62. U.S. Food and Drug Administration — Warning Letter to Glenmark Pharmaceuticals Limited (MARCS-CMS 708270), July 11, 2025.

63. U.S. Food and Drug Administration — Warning Letter to Shiva Analyticals Private Limited (MARCS-CMS 707857), July 23, 2025.

64. U.S. Food and Drug Administration — Warning Letter to Hikal Limited (MARCS-CMS 709370), August 20, 2025.

65. U.S. Food and Drug Administration — Warning Letter to Amneal Pharmaceuticals, LLC (MARCS-CMS 709894), August 27, 2025.

66. U.S. Food and Drug Administration — Warning Letter to Somerset Therapeutics Private Limited (MARCS-CMS 711340), September 04, 2025.

67. U.S. Food and Drug Administration — Warning Letter to Cdymax India Pharma Private Limited (MARCS-CMS 715022), November 13, 2025.

68. U.S. Food and Drug Administration — Warning Letter to Tentamus India Private Limited (MARCS-CMS 720463), March 03, 2026.

69. U.S. Food and Drug Administration — Warning Letter to Flowchem Pharma Private Limited (MARCS-CMS 720719), March 11, 2026.

70. U.S. Food and Drug Administration — Warning Letter to Patcos Cosmetics Pvt. Ltd. (MARCS-CMS 718220), March 12, 2026.

71. U.S. Food and Drug Administration — Warning Letter to Alchymars ICM SM Private Limited (MARCS-CMS 724429), May 21, 2026.

72. U.S. Food and Drug Administration — Warning Letter to Gopaldas Visram & Co., Ltd. (MARCS-CMS 721755), June 02, 2026.

73. U.S. Food and Drug Administration — Warning Letter to Umendra Life Sciences Private Limited (MARCS-CMS 721752), June 02, 2026.

74. U.S. Food and Drug Administration — Warning Letter to Zydus Lifesciences Limited (MARCS-CMS 722576), June 02, 2026.

75. U.S. Food and Drug Administration — Warning Letter to Wizcure Pharmaa Private Limited (MARCS-CMS 726378), June 24, 2026.

76. U.S. Food and Drug Administration — Warning Letter to BioMylz Pvt. Ltd. (MARCS-CMS 729483), July 13, 2026.

77. U.S. Food and Drug Administration — Warning Letter to Shimoga Chemicals (MARCS-CMS 727904), July 13, 2026.